Vancouver, BC, October 25, 2019--TRIUMF, Canada's particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, announced that they have completed the first joint production run of actinium-225, a rare medical isotope that shows great promise as the basis for new, cutting-edge cancer therapies.
|